AU2011223906B2 - Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients - Google Patents
Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients Download PDFInfo
- Publication number
- AU2011223906B2 AU2011223906B2 AU2011223906A AU2011223906A AU2011223906B2 AU 2011223906 B2 AU2011223906 B2 AU 2011223906B2 AU 2011223906 A AU2011223906 A AU 2011223906A AU 2011223906 A AU2011223906 A AU 2011223906A AU 2011223906 B2 AU2011223906 B2 AU 2011223906B2
- Authority
- AU
- Australia
- Prior art keywords
- hcv
- xid
- subject
- cell
- consensus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title claims description 102
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 title claims description 55
- 206010028980 Neoplasm Diseases 0.000 title claims description 52
- 230000036210 malignancy Effects 0.000 title claims description 49
- 239000003550 marker Substances 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 45
- 208000024891 symptom Diseases 0.000 claims abstract description 32
- 238000001514 detection method Methods 0.000 claims abstract description 16
- 238000011161 development Methods 0.000 claims abstract description 11
- 238000013399 early diagnosis Methods 0.000 claims abstract description 9
- 241000711549 Hepacivirus C Species 0.000 claims description 110
- 208000015181 infectious disease Diseases 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 108060003951 Immunoglobulin Proteins 0.000 claims description 20
- 102000018358 immunoglobulin Human genes 0.000 claims description 20
- 150000007523 nucleic acids Chemical group 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 9
- 108010004729 Phycoerythrin Proteins 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 8
- 210000004602 germ cell Anatomy 0.000 claims description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 6
- 239000013060 biological fluid Substances 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108091035707 Consensus sequence Proteins 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 15
- 238000011282 treatment Methods 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 25
- 210000004698 lymphocyte Anatomy 0.000 description 17
- 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 description 16
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 16
- 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 description 16
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 16
- 108010091326 Cryoglobulins Proteins 0.000 description 14
- 208000005176 Hepatitis C Diseases 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 10
- 206010025323 Lymphomas Diseases 0.000 description 9
- 206010047115 Vasculitis Diseases 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 8
- 229920002477 rna polymer Polymers 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 7
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 6
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 230000007882 cirrhosis Effects 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000006154 Chronic hepatitis C Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 101001047618 Homo sapiens Immunoglobulin kappa variable 3-15 Proteins 0.000 description 3
- 102100022965 Immunoglobulin kappa variable 3-15 Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 208000004732 Systemic Vasculitis Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010065051 Acute hepatitis C Diseases 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000037914 B-cell disorder Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 206010022004 Influenza like illness Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 238000013394 immunophenotyping Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101001037153 Homo sapiens Immunoglobulin heavy variable 3-7 Proteins 0.000 description 1
- 101150019496 IGHV1-69 gene Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100040231 Immunoglobulin heavy variable 3-7 Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010056872 Palpable purpura Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 101150046474 Vhl gene Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- AXIKDPDWFVPGOD-UHFFFAOYSA-O [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;2-(2,4,5,7-tetrabromo-3,6-dihydroxyxanthen-10-ium-9-yl)benzoic acid Chemical compound C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21.OC(=O)C1=CC=CC=C1C1=C(C=C(Br)C(O)=C2Br)C2=[O+]C2=C1C=C(Br)C(O)=C2Br AXIKDPDWFVPGOD-UHFFFAOYSA-O 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011509 clonal analysis Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003391 densitometric scan Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000005582 sexual transmission Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000003156 vasculitic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30916110P | 2010-03-01 | 2010-03-01 | |
| US61/309,161 | 2010-03-01 | ||
| PCT/US2011/026455 WO2011109285A2 (en) | 2010-03-01 | 2011-02-28 | Prognostic marker for cryoglobulinemic vasculitis and b cell malignancies in hcv infected patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011223906A1 AU2011223906A1 (en) | 2012-09-13 |
| AU2011223906B2 true AU2011223906B2 (en) | 2015-06-25 |
Family
ID=44542788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011223906A Ceased AU2011223906B2 (en) | 2010-03-01 | 2011-02-28 | Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9719141B2 (enExample) |
| EP (1) | EP2542892A4 (enExample) |
| JP (1) | JP6095984B2 (enExample) |
| AU (1) | AU2011223906B2 (enExample) |
| BR (1) | BR112012021795A2 (enExample) |
| CA (1) | CA2791676A1 (enExample) |
| WO (1) | WO2011109285A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103184216B (zh) * | 2011-12-27 | 2015-03-18 | 深圳华大基因科技有限公司 | 用于扩增免疫球蛋白重链cdr3编码序列的引物组合物及其用途 |
| US11781112B2 (en) | 2016-03-06 | 2023-10-10 | Kareem Thomas Robinson | Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines |
| RU2642626C1 (ru) * | 2016-11-03 | 2018-01-25 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ прогнозирования развития криоглобулинемического васкулита у больных хроническим гепатитом с |
| EP4567822A3 (en) | 2017-08-08 | 2025-09-10 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20020049A1 (it) | 2002-01-30 | 2003-07-30 | Biostrands S R L | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
| US8178303B2 (en) | 2003-12-04 | 2012-05-15 | Wake Forest University Health Sciences | Increasing the speed of cryoglobulin precipitation |
| EP1801116A1 (en) | 2005-12-21 | 2007-06-27 | F. Hoffmann-La Roche Ag | HCV replicon shuttle vectors |
-
2011
- 2011-02-28 CA CA2791676A patent/CA2791676A1/en not_active Abandoned
- 2011-02-28 BR BR112012021795A patent/BR112012021795A2/pt not_active IP Right Cessation
- 2011-02-28 AU AU2011223906A patent/AU2011223906B2/en not_active Ceased
- 2011-02-28 WO PCT/US2011/026455 patent/WO2011109285A2/en not_active Ceased
- 2011-02-28 US US13/581,759 patent/US9719141B2/en not_active Expired - Fee Related
- 2011-02-28 JP JP2012556133A patent/JP6095984B2/ja not_active Expired - Fee Related
- 2011-02-28 EP EP11751140.2A patent/EP2542892A4/en not_active Withdrawn
-
2015
- 2015-09-23 US US14/863,220 patent/US20160083801A1/en not_active Abandoned
-
2017
- 2017-09-11 US US15/701,379 patent/US20180002763A1/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| DE RE, V. et al., International Journal Cancer, 2000, Vol. 87, pages 211-216 * |
| KNIGHT, G. B et al, J. Exp. Med, 1993, Vol. 178, pages 1903-1911 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011109285A3 (en) | 2012-01-19 |
| BR112012021795A2 (pt) | 2016-05-17 |
| US20160083801A1 (en) | 2016-03-24 |
| CA2791676A1 (en) | 2011-09-09 |
| WO2011109285A2 (en) | 2011-09-09 |
| JP2013521497A (ja) | 2013-06-10 |
| CN102859360A (zh) | 2013-01-02 |
| AU2011223906A1 (en) | 2012-09-13 |
| EP2542892A4 (en) | 2013-11-27 |
| US20130052206A1 (en) | 2013-02-28 |
| EP2542892A2 (en) | 2013-01-09 |
| JP6095984B2 (ja) | 2017-03-15 |
| US20180002763A1 (en) | 2018-01-04 |
| US9719141B2 (en) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11320433B2 (en) | Anti-dengue virus NS1 protein monoclonal antibodies | |
| US20180002763A1 (en) | Prognostic Marker For Cryoglobulinemic Vasculitis And B Cell Malignancies In HCV Infected Patients | |
| US20130177575A1 (en) | Novel therapeutic target and diagnostic marker for asthma and related conditions | |
| WO2017175228A1 (en) | Infiltrating immune cell proportions predict anti-tnf response in colon biopsies | |
| Azumagawa et al. | Post-vaccination MDEM associated with MOG antibody in a subclinical Chlamydia infected boy | |
| Knight et al. | Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies | |
| EP2984108B1 (en) | Anti-s100a7 antibodies for the treatment and diagnosis of cancer | |
| JP2013021932A (ja) | 関節リウマチに対する抗ｉｌ−６受容体抗体療法の有効性の予測方法 | |
| KR20180016335A (ko) | 항-lps 면역글로불린 치료에 대한 임상 반응의 예측성 생체표지자 | |
| CN102859360B (zh) | Hcv感染患者中的冷球蛋白血症性血管炎和b细胞恶性肿瘤的预测标志物 | |
| JP2011211970A (ja) | インターフェロンに対する感受性又は応答性を予測する方法、キット及びマーカー遺伝子 | |
| CN119529099B (zh) | 一种抗nse蛋白的抗体或其抗原结合片段、肿瘤诊断产品及其应用 | |
| CN116333110B (zh) | 一种特异性结合afp多肽的结合蛋白、肿瘤诊断试剂盒 | |
| US20230096203A1 (en) | Methods for detecting food allergies | |
| Siukola | SPATIAL TRANSCRIPTOMICS OF CELIAC DISEASE SMALL INTESTINE IN DIFFERENT STAGES OF INFLAMMATION | |
| US20220396613A1 (en) | Treatment and diagnosis of mental disorders | |
| HK40041456A (en) | Anti-dengue virus ns1 protein monoclonal antibodies | |
| Notarnicola | Studies on pathogenesis, clinical features and comorbidities of idiopathic inflammatory myopathies | |
| CN119462932A (zh) | 一种抗cd8的抗体或其抗原结合片段、富集cd8+细胞的产品及其应用 | |
| Lemann et al. | European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting June 3–6, 2009 Budapest, Hungary | |
| WO2024074114A1 (zh) | 一种多表位HCV core抗体组合及检测试剂盒 | |
| RU2020124096A (ru) | Биомаркеры иммунной толерантности, индуцированной метотрексатом | |
| Zili et al. | Posters: Autoimmunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |